Successful 5th International CytoSorb Users Meeting
Just prior to the 38th ISICEM conference, CytoSorbents held its 5th International CytoSorb Users Meeting, relocating to the larger ISICEM conference center from the Hotel Marivaux in years past, to accommodate nearly 150 participants from the growing global CytoSorb community, including physicians, partners, and distributors.
The goal of the meeting was to invite CytoSorb users to share their treatment experiences and research with the group, fostering healthy discussion about how to best optimize treatment in a wide range of different applications. Professor Jean-Louis Vincent, one of the top worldwide KOLs in critical care and the organizer of the ISICEM conference, gave the opening lecture on “The Role of Personalized Medicine on the ICU”, supporting CytoSorbents’ strategy of conducting smaller, but targeted studies in well-defined patient populations. In all, twenty-three speakers and session chairs from ten countries contributed to the meeting, including many of the pioneers of the therapy.
One common theme throughout the majority of the clinical presentations was the valuable role that CytoSorb plays in helping to restore hemodynamic stability in these critically-ill patients. In addition, exciting new mechanistic data highlight the ability of CytoSorb to improve microcirculation and tissue oxygenation, a key physiologic deficit in septic shock, as well as to modulate the immune system on both a cellular and molecular level.
Cytosorbents Europe GmbH, headquartered in Berlin, is a wholly owned subsidiary of CytoSorbents Corporation of Monmouth Junction, New Jersey, USA, where the CytoSorb product is manufactured. CytoSorb is the company’s flagship product, backed by more than 30 patent families.
Welcome: 6th International CytoSorb Users` Meeting
Subscribe to our newsletter now!
Get access to the CytoSorbents Community Area. The current newsletter contains a direct link to the CytoSorbents Community Area.